PMID- 27597944
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160906
LR  - 20200929
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 3
DP  - 2016
TI  - HLA-DQ B1*0201 and A1*0102 Alleles Are Not Responsible for Antituberculosis 
      Drug-Induced Hepatotoxicity Risk in Spanish Population.
PG  - 34
LID - 10.3389/fmed.2016.00034 [doi]
LID - 34
AB  - AIMS: To evaluate the role of human leukocyte antigen (HLA) class II DQB1*0201 
      and DQA1*0102 in the risk of antituberculosis drug (ATD)-induced hepatotoxicity 
      (ATDH) in a cohort of tuberculosis patients of Caucasian origin from Spain. 
      METHODS: Matched case-control study including active tuberculosis (TB) patients 
      from Spain (Caucasian) treated with first-line ATD (Isoniazid, Rifampin, and 
      Pyrazinamide). Presence or absence of HLA class II DQB1*0201 and DQA1*0102 
      alleles were compared between cases and controls. RESULTS: We included 110 TB 
      patients, 55 ATDH cases, and 55 sex-matched controls. The analysis of the 
      presence of HLA-DQB1*0201 and HLA-DQA*0102 did not show significative differences 
      between both groups [presence of HLA-DQB1*0201 53.6% of the cases vs. 45.4% of 
      the controls, OR: 1.63 95% CI (0.62-4.52) p = 0.38; presence of HLA-DQA*0102 7.5% 
      of cases vs. 20% of controls, OR: 0.36 95% CI (0.08-1.23) p = 0.12]. After 
      multivariate logistic regression analysis including in the model, other potential 
      risk factors of hepatotoxicity HLA class II DQB1*0201 and DQA1*0102 alleles were 
      not found significantly associated with the risk of development ATDH. We could 
      not demonstrate an association between HLA-DQA1*0102 and HLA-DQB1*0201 with the 
      risk of ATDH in this Caucasian population of Spanish origin.
FAU - Leiro-Fernandez, Virginia
AU  - Leiro-Fernandez V
AD  - NeumoVigol+i Research Group, Pulmonary Department, EOXI Vigo, Biomedical Research 
      Institute Vigo (IBIV), Alvaro Cunqueiro Hospital , Vigo , Spain.
FAU - Valverde, Diana
AU  - Valverde D
AD  - Biochemical, Genetics and Immunology Department, Biology Faculty, Vigo University 
      , Vigo , Spain.
FAU - Vazquez-Gallardo, Rafael
AU  - Vazquez-Gallardo R
AD  - NeumoVigol+i Research Group, Pulmonary Department, EOXI Vigo, Biomedical Research 
      Institute Vigo (IBIV), Alvaro Cunqueiro Hospital , Vigo , Spain.
FAU - Constenla-Carames, Lucia
AU  - Constenla-Carames L
AD  - Clinic Analysis Department, EOXI Vigo, Alvaro Cunqueiro Hospital , Vigo , Spain.
FAU - Del Campo-Perez, Victor
AU  - Del Campo-Perez V
AD  - Preventive Medicine Department, EOXI Vigo, Alvaro Cunqueiro Hospital , Vigo , 
      Spain.
FAU - Fernandez-Villar, Alberto
AU  - Fernandez-Villar A
AD  - NeumoVigol+i Research Group, Pulmonary Department, EOXI Vigo, Biomedical Research 
      Institute Vigo (IBIV), Alvaro Cunqueiro Hospital , Vigo , Spain.
LA  - eng
PT  - Journal Article
DEP - 20160822
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC4992991
OTO - NOTNLM
OT  - DQA1*0102
OT  - DQB1*0201
OT  - first-line antituberculosis drugs
OT  - hepatitis
OT  - pharmacogenetics susceptibility
EDAT- 2016/09/07 06:00
MHDA- 2016/09/07 06:01
PMCR- 2016/08/22
CRDT- 2016/09/07 06:00
PHST- 2016/02/16 00:00 [received]
PHST- 2016/07/29 00:00 [accepted]
PHST- 2016/09/07 06:00 [entrez]
PHST- 2016/09/07 06:00 [pubmed]
PHST- 2016/09/07 06:01 [medline]
PHST- 2016/08/22 00:00 [pmc-release]
AID - 10.3389/fmed.2016.00034 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2016 Aug 22;3:34. doi: 10.3389/fmed.2016.00034. eCollection 
      2016.